Read by QxMD icon Read

Recent Patents on Anti-cancer Drug Discovery

Martin Perez-Santos, Maricruz Anaya-Ruiz, Cindy Bandala
BACKGROUND: Data mining publications and patent data can provide decision support for scientists, inventors and industry in the field of cancer research. OBJECTIVE: The main objective of this article it to identify trends of research and patent generation productivity originating from Latin American countries in the field of cancer. METHOD: Publications were collected from the Scopus, Web of Science, PubMed database; and patents were collected from Latipat Espacenet databases...
October 13, 2016: Recent Patents on Anti-cancer Drug Discovery
Marco Scianna, Luca Munaron
BACKGROUND: Cancer is a heterogeneous disease, which is based on an intricate network of processes at different spatiotemporal scales, from the genome to the tissue level. Hence the necessity for the biomedical and pharmaceutical research to work in a multiscale fashion. In this respect, a significant help derives from the collaboration with theoretical sciences. Indeed, mathematical models can provide insights into tumor-related processes and support clinical oncologists in the design of treatment regime, dosage, schedule and toxicity...
October 3, 2016: Recent Patents on Anti-cancer Drug Discovery
Anuj Rathi, Riyaz Syed, Vijay Singh, Han-Seung Shin, Rahul V Patel
Cancer accounts for a numbers of deaths each year. Consequently, prevention of this deadly disease though the invention of new anticancer agents is of utmost importance. The current review elaborates the importance of indole designs as patented in the form of anticancer drug-like molecules targeting different cites of biological arena, specifically kinases such as platelet-derived growth factor receptor, vascular endothelial growth factor receptor and fibroblast growth factor receptor, Bruton's tyrosine kinase, anaplastic lymphoma kinase, Janus kinase, cyclin-dependent kinase aurora kinases A, B and C, checkpoint kinases, protein kinase R, Pim kinases, phosphoinositide 3-kinase, altered proteins kinases, polo-like kinase and many more...
October 3, 2016: Recent Patents on Anti-cancer Drug Discovery
Maryam Iman, Zeynab Khansepid, Asghar Davood
BACKGROUND: Ribonucleotide Reductase (RNR) is an important anticancer chemotherapy target. It has main key role in DNA synthesis and cell growth. Therefore several RNR inhibitors, such as Hydroxyurea, have entered the clinical trials. Based on our proposed mechanism, radical site of RNR protein reacts with Hydroxyurea in which hydroxyurea is converted into its oxidized form compound III, and whereby the tyrosyl radical is converted into a normal tyrosine residue. OBJECTIVE: In this study, docking and molecular dynamics simulations were used for proposed molecular mechanism of Hydroxyurea in RNR inhibition as anticancer agent...
September 26, 2016: Recent Patents on Anti-cancer Drug Discovery
Lina Yu, Jun Ma, Jichun Han, Bo Wang, Xiaoyu Chen, Caixia Gao, Defang Li, Qiusheng Zheng
BACKGROUND: Recently patent of Licochalcone B (LCB) as Anti-inflammatory agent has been developed. Emerging evidence showed that Licochalcone B (LCB) could be a promising alternative compound with anti-cancer activities. However, the anti-cancer mechanism of LCB in MCF-7 cells has not been fully investigated. OBJECTIVE: We aimed to unearth the anti-cancer effects and mechanism of LCB in breast cancer cells. METHOD: Cell proliferation and cell cycle were determined by sulforhodamine B assay and flow cytometry, respectively...
September 5, 2016: Recent Patents on Anti-cancer Drug Discovery
Chie Hoon Song, Janghyeok Yoon, Namuk Ko, Jeung-Whan Han
BACKGROUND: Epigenetics is a biomedical novelty in drug design and disease control whose mechanisms play a significant role in transferring environmental signals to determine patterns of gene expression. Systematic identification of the main trends in epigenetics patenting activity provides insights into fundamental building blocks of this research field and policy guidance to funding agencies. OBJECTIVE: The review aims at providing a comprehensive overview of the research and development trend in epigenetics by mapping the knowledge structure in patent landscape...
August 25, 2016: Recent Patents on Anti-cancer Drug Discovery
Tian-Yun Wang, Junhe Junhe Zhang, Ailing Du, Li Li Wang, Xiaoyin Wang, Jian-Hui Gao
BACKGROUND: Gene therapy is a promising approach for the treatment of various cancers. However, most viral vectors used for this purpose carry risks, including potential integration into the host genome. OBJECTIVE: We addressed this issue in the present study by constructing an episomal lentiviral vector using the β-interferon matrix attachment region to express the microRNA -145 (miR-145), and examining the effect of miR-145 overexpression on human esophageal carcinoma (EC) cells...
August 22, 2016: Recent Patents on Anti-cancer Drug Discovery
Ramon Andrade Bezerra De Mello, Davi Jing Jue Liu, Pedro N Aguiar, Hakaru Tadokoro
: Non-small cell lung cancer is the leading cancer-related cause of death. OBJECTIVE: We review the latest therapies for NSCLC with EGFR and ELM4-ALK mutations as well as the most relevant studies and promising patents. METHOD: A literature search of PubMed database was carried out to identify recent Clinical Trials using EGFR therapies and novel patents involving diagnosis and therapies on NSCLC. We conducted a search to find new therapy strategies, new biomarkers, and selected five patents we find relevant...
August 2, 2016: Recent Patents on Anti-cancer Drug Discovery
Minsig Choi, Harold Bien, Gerardo G Mackenzie
Effective therapies against metastatic pancreatic cancer remain limited, and despite treatment, many will ultimately progress. Previously, few options were available for second line therapy in metastatic pancreatic cancer. Liposomal encapsulated irinotecan, in combination with leucovorin-modulated fluorouracil, was found to significantly increase overall survival in patients who have progressed after gemcitabine-based therapy in a large, international, randomized clinical trial (NAPOLI-1). We reviewed the background of systemic therapy for metastatic pancreatic cancer, examined putative mechanisms for the success of encapsulated drugs, and identified recent patent applications on the use of liposomal irinotecan in pancreatic cancer...
July 28, 2016: Recent Patents on Anti-cancer Drug Discovery
Alexander Tishin, Alexander A Shtil, Alexander P Pyatakov, Vladimir I Zverev
BACKGROUND AND OBJECTIVE: Methods of local or loco-regional anticancer treatment are of the utmost importance because the therapeutic 'power' is applied directly to the disease site. Consequently, general toxicity is minimized. Hyperthermia, that is, a sustained increase of intratumoral temperature up to 45 oC, has been investigated as a perspective treatment modality alone and/or in combination with ionizing radiation or chemotherapy. Still, the surrounding tissues can be damaged by the external heat...
July 19, 2016: Recent Patents on Anti-cancer Drug Discovery
Kunal Nepali, Arshdeep Singh, Navdeep Kaur, Gurpreet Singh, Sahil Sharma, Pooja Sharma
BACKGROUND: Topoisomerases are a set of nuclear enzymes that have been established as one of the principal feature in handling of topological consequences of DNA during various genetic activities necessary for vitality of cell. Inhibition of these enzymes consequently leads to the blockage of ligation step of the cell cycle which generates single and double strand breakage in DNA strand. Introduction of these breaks subsequently leads to programmed cell death (Apoptosis). OBJECTIVE: In the past several years, topoisomerases have become one of the most expedient and strategic molecular targets for anticancer drugs and numerous patents have been filed and published on topoisomerase inhibitors...
July 19, 2016: Recent Patents on Anti-cancer Drug Discovery
Giovanni Vitale, Alessandra Dicitore, Erika Messina, Concetta Sciammarella, Antongiulio Faggiano, Annamaria Colao
BACKGROUND: Medullary thyroid carcinoma (MTC) originates from the parafollicular C cells of the thyroid gland. Mutations of the RET proto-oncogene are implicated in the pathogenesis of MTC. Germline activating mutations of this gene have been reported in about 88-98% of familial MTCs, while somatic mutations of RET gene have been detected in about 23-70% of sporadic forms. Although these genetic events are well characterized, much less is known about the role of epigenetic abnormalities in MTC...
2016: Recent Patents on Anti-cancer Drug Discovery
Pascale Moreau, Fabrice Anizon, Francis Giraud, Yannick J Esvan
This review, of the literature published between 2010 and 2015 reports that molecules containing a non-fused and/or fused pyrazole moiety could exhibit very potent activity toward Pim kinases, including the inhibition of cellular Bad phosphorylation as well as antiproliferative activity against various cancer cells. Even if Pim kinase inhibitors currently in clinical trial do not exhibit a pyrazole moiety, heteroaromatic kinase inhibitors containing an indazole part such as Axitinib and Pazopanib already reached the market...
2016: Recent Patents on Anti-cancer Drug Discovery
Amélie Fouqué, Mickael Jean, Pierre van de Weghe, Patrick Legembre
BACKGROUND: Constitutive activation of the PI3K/mTOR signaling pathway is observed in most, if not all, breast cancers. Accordingly, many PI3K and/or mTOR inhibitors have entered clinical trials, and completed studies should soon reveal the efficacy of these new drug families in the treatment of cancer patients. OBJECTIVE: We present the PI3K/Akt/mTOR signaling pathway and the structure and the anti-tumor efficiency of some mTOR inhibitors such as rapalogues and competitive inhibitors, which have entered clinical trials...
2016: Recent Patents on Anti-cancer Drug Discovery
Elahe Qudjani, Maryam Iman, Asghar Davood, Mahdi F Ramandi, Abbas Shafiee
BACKGROUND: Curcumin is a polyphenolic natural compound with multiple targets that used for the prophylaxis and treatment of some type of cancers like cervical and pancreatic cancers. Some recent patent for curcumin for cancer has also been reviewed. OBJECTIVE: In this study, ten new curcumin derivatives were designed and synthesized and their cytostatic activity evaluated against the Hela and Panc cell lines that some of them showed more activity than curcumin...
2016: Recent Patents on Anti-cancer Drug Discovery
Huaming Sheng, Weijuan Tang
BACKGROUND: The aerobic glycolysis in tumor cells known as Warburg effect is one of the most important hallmarks of cancer. It is proposed that the upregulation of the series of metabolic enzymes along the glycolytic pathway may contribute to the Warburg effect. OBJECTIVES: The inhibition of these glycolytic enzymes has been found to be a novel strategy for anticancer treatment. This review summaries recent patents in the development of small molecule inhibitors for the key enzymes in tumor glycolysis...
2016: Recent Patents on Anti-cancer Drug Discovery
Zsuzsanna Suba
BACKGROUND: Results of long-term studies justify that the rate of breast cancer recurrence and tumor-related mortality remains quite unpredictable, regardless of the use of any current therapeutic measures. OBJECTIVE: Since the application of standard therapies, such as surgery, radiation, chemotherapy and antiestrogen administration does not work as might be expected; our therapeutic practice requires thorough rethinking. METHOD: Published long-term therapeutic results on breast cancer cases were analyzed in correlation with stage at diagnosis, ER-status of tumors and patients' age...
2016: Recent Patents on Anti-cancer Drug Discovery
Hisato Kawakami, Kimio Yonesaka
UNLABELLED: Emerging evidence suggests that human epidermal growth factor receptor 3 plays a critical role in cell-survival and drug-resistance in cancer cells. Several kinds of agents targeting this receptor are currently progressing through preclinical or clinical investigations. These agents are usually monoclonal antibodies with unique characteristics, and some have shown efficacy and been welltolerated in clinical trials. For example, patritumab and seribantumab are thought to compete with ligand binding and have proven efficacy for some malignancies in Phase II clinical trials...
2016: Recent Patents on Anti-cancer Drug Discovery
Jinzheng Wang, Xiaoan Wen, Jun Liu, Hongbin Sun
Recent studies show that enhanced mitochondrial biogenesis can "fuel" the cancer cells to grow and migrate. It is therefore proposed that inhibiting the mitochondrial biogenesis could be a new approach to cancer therapy. This review summarizes recent patents and papers in the development of small molecule inhibitors of key regulators responsible for tumor mitochondrial biogenesis, including PPARγcoactivator-1α(PGC-1α), PPARγcoactivator-1β, estrogen-related receptor family (ERRs), estrogen receptor α(ERα), mammalian target of rapamycin, c-Myc and PPARs...
2016: Recent Patents on Anti-cancer Drug Discovery
Xiao-Yang Hou, Guan Jiang, Chun-Sheng Yang, Jian-Qin Tang, Zhi-Ping Wei, Yan-Qun Liu
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. However, the inherent limitations of traditional surgery and insensitivity to radiation and chemotherapy result in failing treatment and poor prognosis. In recent years, the development and advances of nanotechnology has brought new hope for the diagnosis and treatment of HCC. This article reviews the development of nanoparticles used for cancer detection, diagnosis and treatment due to their large specific surface area and unique optical, electronic and magnetic properties...
2016: Recent Patents on Anti-cancer Drug Discovery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"